Standardized Clinical Assessment of Patients With Leptomeningeal

See also
Status	Clinical Trial	Phase
Terminated	`NCT05414123` - A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
Recruiting	`NCT06058988` - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer	Phase 2
Completed	`NCT04178343` - Tomotherapy for Leptomeningeal Metastases	N/A
Recruiting	`NCT06399926` - Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir
Not yet recruiting	`NCT06441045` - Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI	Phase 2
Recruiting	`NCT04425681` - Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer	Phase 2
Recruiting	`NCT05598853` - Intrathecal Double Checkpoint Inhibition	Phase 1
Recruiting	`NCT02803619` - A Multi-center Prospective Observational Biomarker Study on EGFRm+ Non-small Cell Lung Cancer Patients With Leptomeningeal Metastasis	N/A
Recruiting	`NCT05746754` - Proton Cranio-spinal Irradiation for Leptomeningeal Metastasis	N/A
Not yet recruiting	`NCT04148898` - Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis	Phase 2
Completed	`NCT04420598` - DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease	Phase 2
Completed	`NCT02071056` - Circulating Tumor DNA in Cerebrospinal Fluid as an Early Biomarker of Leptomeningeal Metastasis (LM)
Recruiting	`NCT05385185` - Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer	Phase 2
Terminated	`NCT04729348` - Pembrolizumab And Lenvatinib In Leptomeningeal Metastases	Phase 2
Recruiting	`NCT06304441` - Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer	N/A
Not yet recruiting	`NCT06296745` - Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.	Phase 2
Recruiting	`NCT04778800` - A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)	N/A
Not yet recruiting	`NCT06282874` - Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases	Phase 4
Not yet recruiting	`NCT04356222` - Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis	Phase 4
Not yet recruiting	`NCT04356118` - Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis	Phase 4

NCT number	NCT06417710
Study type	Observational
Source	University of Zurich
Contact
Status	Recruiting
Phase
Start date	January 30, 2022
Completion date	December 2026

Standardized Clinical Assessment of Patients With Leptomeningeal Metastasis — NANO-LM

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms